FMP
89bio, Inc.
ETNB
NASDAQ
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
8.13 USD
-0.45 (-5.54%)
About
ceo
Mr. Rohan Palekar
sector
Healthcare
industry
Biotechnology
website
https://www.89bio.com
exchange
NASDAQ
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
CIK
0001785173
ISIN
US2825591033
CUSIP
282559103
Address
142 Sansome Street
Phone
415 432 9270
Country
US
Employee
70
IPO Date
Nov 11, 2019
Key Executives
